GPN Vaccines is dedicated to developing innovative vaccines that provide robust protection against significant bacterial pathogens, particularly targeting Streptococcus pneumoniae, which is responsible for severe diseases such as pneumonia and meningitis. The company employs a unique approach by utilizing proprietary strains of whole bacteria that are modified to ensure safety and high immunogenicity. Their vaccines are produced in a state-of-the-art facility in Australia, where bacterial strains are grown and then inactivated using gamma irradiation. This method preserves the essential structure of bacterial surface proteins, which are crucial for eliciting an effective immune response, and allows the vaccines to target proteins beneath the bacterial capsule, offering broad-spectrum protection against various strains.

The urgency of GPN Vaccines' mission is underscored by the global challenge posed by bacterial infections, which continue to result in millions of deaths annually. Current vaccines often fall short due to issues like serotype replacement and the emergence of antibiotic-resistant bacteria. GPN Vaccines aims to address these challenges by creating whole-cell vaccines that do not require adjuvants, thus enhancing safety and efficacy. Their lead product, Gamma-PN, is designed to protect against all serotypes of S. pneumoniae, making it a promising solution in the fight against bacterial infections and a significant advancement in vaccine technology.

Australia

GPN Vaccines is a biotechnology company developing a Streptococcus pneumoniae vaccine. S. pneumoniae is a major pathogen found largely in the respiratory tract, and there are 100 known serotypes of S. pneumoniae. The company is focused on developing a broad-spectrum vaccine against Streptococcus pneumoniae, which causes life-threatening pneumonia and meningitis. GPN Vaccines has reported positive safety and immunogenicity data from its phase 1 trial of Gamma-PN™, a proprietary engineered whole-cell vaccine against Streptococcus pneumoniae.

Infectious Diseases

University of Adelaide, Adelaide, SA 5005, AU

GPN Vaccines

Company Details